Background: The Lance-Adams syndrome (LAS) is a myoclonus syndrome caused by hypoxic-ischemic encephalopathy. LAS cases could be refractory to first-line medications, and the neuronal mechanism underlying LAS pathology remains unknown. Objectives: To describe a patient with LAS who underwent bilateral globus pallidus internus (GPi) stimulation and discuss the pathophysiology of LAS with intraoperative electrophysiological findings. Patients: A 79-year-old woman presented with a history of cardiopulmonary arrest due to internal carotid artery rupture following carotid endarterectomy after successful cardiopulmonary resuscitation. However, within 1 month, the patient developed sensory stimulation-induced myoclonus in her face and extremities. Because her myoclonic symptoms were refractory to pharmacotherapy, deep brain stimulation of the GPi was performed 1 year after the hypoxic attack. Results: Continuous bilateral GPi stimulation with optimal parameter settings remarkably improved the patient’s myoclonic symptoms. At the 2-year follow-up, her Unified Myoclonus Rating Scale score decreased from 90 to 24. In addition, we observed burst firing and interburst pause patterns on intraoperative microelectrode recordings of the bilateral GPi and stimulated this area as the therapeutic target. Conclusion: Our results show that impairment in the basal ganglion circuitry might be involved in the pathogenesis of myoclonus in patients with LAS.

1.
Levy
A
,
Chen
R
.
Myoclonus: Pathophysiology and Treatment Options
.
Curr Treat Options Neurol
.
2016
May
;
18
(
5
):
21
.
[PubMed]
1092-8480
2.
Dawson
GD
.
Investigations on a patient subject to myoclonic seizures after sensory stimulation
.
J Neurol Neurosurg Psychiatry
.
1947
Nov
;
10
(
4
):
141
62
.
[PubMed]
0022-3050
3.
Shibasaki
H
,
Yamashita
Y
,
Neshige
R
,
Tobimatsu
S
,
Fukui
R
.
Pathogenesis of giant somatosensory evoked potentials in progressive myoclonic epilepsy
.
Brain
.
1985
Mar
;
108
(
Pt 1
):
225
40
.
[PubMed]
0006-8950
4.
Kakigi
R
,
Shibasaki
H
.
Generator mechanisms of giant somatosensory evoked potentials in cortical reflex myoclonus
.
Brain
.
1987
Oct
;
110
(
Pt 5
):
1359
73
.
[PubMed]
0006-8950
5.
Ikeda
A
,
Shibasaki
H
,
Nagamine
T
,
Xu
X
,
Terada
K
,
Mima
T
, et al.
Peri-rolandic and fronto-parietal components of scalp-recorded giant SEPs in cortical myoclonus
.
Electroencephalogr Clin Neurophysiol
.
1995
Jul
;
96
(
4
):
300
9
.
[PubMed]
0013-4694
6.
Yamada
K
,
Sakurama
T
,
Soyama
N
,
Kuratsu
J
.
Gpi pallidal stimulation for Lance-Adams syndrome
.
Neurology
.
2011
Apr
;
76
(
14
):
1270
2
.
[PubMed]
0028-3878
7.
Asahi
T
,
Kashiwazaki
D
,
Dougu
N
,
Oyama
G
,
Takashima
S
,
Tanaka
K
, et al.
Alleviation of myoclonus after bilateral pallidal deep brain stimulation for Lance-Adams syndrome
.
J Neurol
.
2015
Jun
;
262
(
6
):
1581
3
.
[PubMed]
0340-5354
8.
Ramdhani
RA
,
Frucht
SJ
,
Kopell
BH
.
Improvement of post-hypoxic myoclonus with bilateral pallidal deep brain stimulation: A case report and review of the literature
.
Tremor Other Hyperkinet Mov (N Y)
.
2017
May
;
7
:
461
.
[PubMed]
2160-8288
9.
Frucht
SJ
,
Leurgans
SE
,
Hallett
M
,
Fahn
S
.
The unified myoclonus rating scale
.
Adv Neurol
.
2002
;
89
:
361
76
.
[PubMed]
0091-3952
10.
Lance
JW
,
Adams
RD
.
The syndrome of intention or action myoclonus as a sequel to hypoxic encephalopathy
.
Brain
.
1963
Mar
;
86
(
1
):
111
36
.
[PubMed]
0006-8950
11.
Frucht
SJ
,
Trost
M
,
Ma
Y
,
Eidelberg
D
.
The metabolic topography of posthypoxic myoclonus
.
Neurology
.
2004
May
;
62
(
10
):
1879
81
.
[PubMed]
0028-3878
12.
Chadwick
D
,
Hallett
M
,
Harris
R
,
Jenner
P
,
Reynolds
EH
,
Marsden
CD
.
Clinical, biochemical, and physiological features distinguishing myoclonus responsive to 5-hydroxytryptophan, tryptophan with a monoamine oxidase inhibitor, and clonazepam
.
Brain
.
1977
Sep
;
100
(
3
):
455
87
.
[PubMed]
0006-8950
13.
Kobayashi
K
,
Katayama
Y
,
Otaka
T
,
Obuchi
T
,
Kano
T
,
Nagaoka
T
, et al.
Thalamic deep brain stimulation for the treatment of action myoclonus caused by perinatal anoxia
.
Stereotact Funct Neurosurg
.
2010
;
88
(
4
):
259
63
.
[PubMed]
1011-6125
14.
Welter
ML
,
Grabli
D
,
Karachi
C
,
Jodoin
N
,
Fernandez-Vidal
S
,
Brun
Y
, et al.
Pallidal activity in myoclonus dystonia correlates with motor signs
.
Mov Disord
.
2015
Jun
;
30
(
7
):
992
6
.
[PubMed]
0885-3185
15.
Vitek JL, Chockkan V, Zhang J-Y, Kaneoke Y, Evatt M, DeLong MR, et al. Neuronal activitiy in the basal ganglia in patients with generalized dystonia and hemiballismus. Ann Neurol. 1999;46:22–35.
16.
Silberstein
P
,
Kühn
AA
,
Kupsch
A
,
Trottenberg
T
,
Krauss
JK
,
Wöhrle
JC
, et al.
Patterning of globus pallidus local field potentials differs between Parkinson’s disease and dystonia
.
Brain
.
2003
Dec
;
126
(
Pt 12
):
2597
608
.
[PubMed]
0006-8950
17.
Liu
X
,
Wang
S
,
Yianni
J
,
Nandi
D
,
Bain
PG
,
Gregory
R
, et al.
The sensory and motor representation of synchronized oscillations in the globus pallidus in patients with primary dystonia
.
Brain
.
2008
Jun
;
131
(
Pt 6
):
1562
73
.
[PubMed]
0006-8950
18.
Barow
E
,
Neumann
WJ
,
Brücke
C
,
Huebl
J
,
Horn
A
,
Brown
P
, et al.
Deep brain stimulation suppresses pallidal low frequency activity in patients with phasic dystonic movements
.
Brain
.
2014
Nov
;
137
(
Pt 11
):
3012
24
.
[PubMed]
0006-8950
19.
Roze
E
,
Lang
AE
,
Vidailhet
M
.
Myoclonus-dystonia: classification, phenomenology, pathogenesis, and treatment
.
Curr Opin Neurol
.
2018
Aug
;
31
(
4
):
484
90
.
[PubMed]
1350-7540
20.
Zimprich
A
,
Grabowski
M
,
Asmus
F
,
Naumann
M
,
Berg
D
,
Bertram
M
, et al.
Mutations in the gene encoding epsilon-sarcoglycan cause myoclonus-dystonia syndrome
.
Nat Genet
.
2001
Sep
;
29
(
1
):
66
9
.
[PubMed]
1061-4036
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.